1. Home
  2. CKX vs SKYE Comparison

CKX vs SKYE Comparison

Compare CKX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CKX Lands Inc.

CKX

CKX Lands Inc.

N/A

Current Price

$10.70

Market Cap

23.5M

Sector

Energy

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$0.51

Market Cap

20.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CKX
SKYE
Founded
1930
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.5M
20.0M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
CKX
SKYE
Price
$10.70
$0.51
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
4.5K
119.5K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
1125.00
N/A
EPS
0.09
N/A
Revenue
$838,543.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$117.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.66
$0.28
52 Week High
$13.00
$4.99

Technical Indicators

Market Signals
Indicator
CKX
SKYE
Relative Strength Index (RSI) 47.45 36.49
Support Level $10.21 $0.28
Resistance Level $11.31 $0.84
Average True Range (ATR) 0.51 0.08
MACD -0.03 -0.00
Stochastic Oscillator 26.60 40.86

Price Performance

Historical Comparison
CKX
SKYE

About CKX CKX Lands Inc.

CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way, and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. It has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Timber segment.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: